Novo Nordisk’s obesity drug to begin end-stage trials in early 2026
HQ Team July 13, 2025: Denmark’s Novo Nordisk A/S will advance its experimental drug amycretin, in both injection and oral forms, into end-stage.
Drugs
Health
Pharma
Drugs
Health
Medical
Bionic pancreas for better management of Type1 diabetes
Trials found bionic pancreas to be more effective in delivering required doses of insulin